Table 1
SCCA-IgM serological levels in patients with HCV infection and cirrhosis
| SCCA-IgM | DB 1 | DB 2 | DB 3 | DB 4 | DB 5 | DB 6 | TOT |
|---|---|---|---|---|---|---|---|
| ≥0 AU/mL | 272 100% | 127 100% | 67 100% | 76 100% | 24 100% | 31 100% | 597 100% |
| >50 AU/mL | 206 76% | 106 84% | 61 91% | 32 42% | 22 92% | 31 100% | 458 77% |
| >200 AU/mL | 121 44% | 52 41% | 29 43% | 51 67% | 7 29% | 18 58% | 278 47% |
| >300 AU/mL | 88 32% | 37 29% | 20 30% | 34 45% | 7 29% | 10 32% | 196 33% |
| >500 AU/mL | 67 25% | 24 19% | 16 24% | 19 25% | 5 21% | 2 7% | 133 22% |
| >600 AU/mL | 60 22% | 18 14% | 13 19% | 13 17% | 3 13% | 2 7% | 109 18% |
Table 2
SCCA-IgM levels and timing of HCC development in patients with HCV infection and cirrhosis
| SCCA-IgM | HCC 12 months % | HCC 6 months % | HCC 4 months % |
|---|---|---|---|
| ≤50 AU/mL | 0/16 0% | 0/16 0% | 0/16 0% |
| >50 AU/mL | 24/287 8,4% | 11/287 3,8% | 10/287 3,5% |
| >500 AU/mL | 7/63 11,1% | 5/63 7,9% | 5/63 7,9% |
Table 3
number of HCC and relative costs and savings associated with the monitoring of HCV-cirrhotic patients in Italy.
| Annual cost of US only every 6 months | €46.516.400 |
| Annual cost of SCCA-IgM analysis | €4.008.069 |
| Costs saved by doing 1 US/year instead of 2 | €5.247.488 |
| Net costs of SCCA-IgM+US/year | €45.276.981 |
| Annual saving of SCCA-IgM+US vs. US only | €1.239.419 |
| HCC identified/year | €11.974 |
| Cost of US only/HCC identified | €3.885 |
| Cost of SCCA-IgM+US/HCC identified | €3.781 |
| Saving/HCC identified | €104 |
Figure 1
Monitoring of HCV-cirrhotic patients according to the current method (blue path) and the new alternative model (green path).